GET DAILY SIGNALSWhy Is Gyre Therapeutics (GYRE) Stock Up +9.73% Today?
Key Takeaways
- GYRE shares advanced 9.73% to $4.40, up from the prior session's close of $4.01.
- The rally followed a third-quarter earnings beat, with revenue of $32.93 million topping the roughly $26.47 million consensus estimate.
- GAAP earnings per share of $(0.04) came in above the consensus forecast of about $(0.073), reinforcing the positive reaction.
- Management reaffirmed full-year 2026 revenue guidance of $100.5 million to $111.0 million.
- Investors also weighed pipeline progress, including the priority review of the F351 (hydronidone) drug candidate in China.
- For more context on valuation and analyst expectations, explore Price Targets, Earnings, and Forecast data.
- To see how AI-driven strategies are positioning across the market, visit Trending AI Robots.
Opening Summary
Gyre Therapeutics, Inc. (GYRE), a commercial-stage biopharmaceutical company developing anti-inflammatory and anti-fibrotic therapies with operations in the United States and China, moved sharply higher on Thursday. The stock climbed 9.73% to $4.40, compared with the previous session's close of $4.01, a gain of $0.39 per share. Markets attributed the advance to better-than-expected third-quarter financial results released after the prior close, along with reaffirmed annual guidance and ongoing clinical pipeline momentum.
Third-Quarter Earnings Beat Drives the Rally
The primary catalyst behind the move was an earnings-driven rally following Gyre Therapeutics' third-quarter results. The company reported revenue of $32.93 million, comfortably exceeding the consensus estimate of roughly $26.47 million. On the bottom line, GAAP basic earnings per share of $(0.04) beat the consensus forecast of approximately $(0.073), a smaller-than-expected loss that reassured investors about the trajectory of the business.
The revenue outperformance was led by the company's lead product, ETUARY (pirfenidone), used in idiopathic pulmonary fibrosis. ETUARY sales rose about 13% year over year to roughly $31.4 million, reflecting increased marketing-driven sales volume. The gains were partially offset by lower contributions from other products and the conclusion of a collaboration agreement with Astellas in March 2026, but the headline beat was enough to fuel renewed buying interest.
Guidance Reaffirmation and Pipeline Progress
Beyond the headline numbers, management reaffirmed its full-year 2026 revenue guidance of $100.5 million to $111.0 million, a signal that the company expects its commercial and clinical momentum to continue through year-end. The confirmation removed some uncertainty and supported the positive market reaction.
Investors also focused on the clinical pipeline. The new drug application for F351 (hydronidone), targeting chronic hepatitis B-related liver fibrosis, was accepted by China's Center for Drug Evaluation and granted priority review earlier in 2026. The company completed an on-site inspection during the third quarter and indicated that a regulatory decision could arrive in late 2026 or the first quarter of 2027. This near-term catalyst has kept attention on the stock even amid a challenging year-to-date performance.
Market Context and Trading Activity
The rally followed a volatile stretch for the shares, which had declined in the prior session ahead of the earnings release. Thursday's rebound reflected a reversal as investors digested the results. Trading activity pointed to renewed conviction, with the stock recovering toward levels seen earlier in the week after the post-earnings beat.
The move was company-specific rather than a broad sector event, driven primarily by the earnings surprise rather than a rally in biotech benchmarks. While small-cap and clinical-stage biopharmaceutical names can be sensitive to broader risk appetite, the scale of Thursday's advance pointed to stock-specific catalysts centered on the earnings report and guidance.
What Comes Next for GYRE
Looking ahead, traders are watching several factors for GYRE. The most significant near-term event is the potential regulatory decision on F351 in China, expected in late 2026 or the first quarter of 2027, which could meaningfully reshape the company's addressable market. Additional clinical updates, including early-stage oncology and hematology programs following the Cullgen merger, will also be monitored.
Risks remain. The company posted an operating loss in the third quarter as acquisition-related and clinical development expenses rose, and cash reserves declined relative to year-end levels. Competitive dynamics in China's centralized procurement environment have pressured some legacy product sales. How analyst estimates evolve in the wake of the earnings beat will be a key factor in whether the current momentum can be sustained.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of AI-driven trading bots, chosen from hundreds of available strategies covering thousands of tickers. Only the strongest performers under current market conditions are featured, with bots differing by strategy, timeframe, performance metrics, and traded symbols. Explore the page to see which automated approaches are currently generating the most attention.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
GYRE in upward trend: price may ascend as a result of having broken its lower Bollinger Band on October 30, 2026
GYRE may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 28 of 32 cases where GYRE's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 88%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +16.80% 3-day Advance, the price is estimated to grow further. Considering data from situations where GYRE advanced for three days, in 216 of 260 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on GYRE as a result. In 76 of 95 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 80%.
The Moving Average Convergence Divergence Histogram (MACD) for GYRE turned negative on October 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In 36 of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at 86%.
GYRE moved below its 50-day moving average on October 29, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for GYRE crossed bearishly below the 50-day moving average on October 15, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 16 of 19 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 84%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GYRE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
The Aroon Indicator for GYRE entered a downward trend on November 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 10 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.940) is normal, around the industry mean (2.788). P/E Ratio (-20.050) is within average values for comparable stocks, (-0.376). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (133.911) among similar stocks. P/S Ratio (6.536) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 86 (best 1 - 100 worst), indicating slightly worse than average price growth. GYRE’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 95 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 98 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GYRE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement